SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as the community rallies to maintain visibility and momentum while working through technical ticker issues on platform aggregators. Holders are actively coordinating on social channels to foster organic growth and build a long-term community project focused on sustainability and transparency.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community eagerly awaits the official reveal of the ES9 luxury SUV, which many expect to be a major catalyst for future growth and market share expansion. Investors are actively discussing the company's aggressive technological push and strong delivery momentum, fueling intense debate over potential institutional rotation and the ongoing battle between long-term bulls and short sellers.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate the impact of agentic AI competition against the company's strong fundamentals and established enterprise role. While the community remains polarized by recent volatility and technical support levels, many are focused on the upcoming product showcase as a potential catalyst to shift the narrative and challenge short interest.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the focal point of intense market debate as investors weigh a recent FSD approval in the Netherlands against persistent concerns over shrinking margins and potential demand issues. While bulls point to vertical integration and future autonomous breakthroughs as long-term catalysts, the community is actively divided between those hunting for a major short squeeze and others bracing for further downside amid ongoing regulatory scrutiny.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon is trending due to speculative M&A headlines involving a potential multibillion-dollar buyout offer from Sun Pharma, leading to intense social media debate over deal credibility and the company's significant debt load. Traders are closely monitoring the high volume and volatility as they weigh the binary risk of a deal announcement against the company's fundamental challenges.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a massive $21 billion contract expansion with Meta through 2032 and a new multi-year partnership with Anthropic to power its Claude AI models. While the community is excited about these major AI infrastructure wins and the company's deepening ties to industry leaders, sentiment is being tempered by concerns over the concurrent $3.5 billion convertible note offering and ongoing dilution fears.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging as investors anticipate the upcoming topline Phase 2/3 OptimUM-02 trial results for its lead asset, darovasertib, in metastatic uveal melanoma. The community is actively discussing the potential for an accelerated approval filing and a commercial-stage transition, with many traders closely monitoring for high-volume price action and potential institutional accumulation ahead of the data release.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending following a decline in quarterly operating earnings and investor scrutiny surrounding the transition to new leadership under Greg Abel. While some community members express frustration over stagnant performance and the company's massive cash hoard, others view the current price drop as a strategic buying opportunity, betting on the firm's defensive stability and potential for future capital deployment.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is experiencing significant volatility and heavy trading volume as investors react to a strategic pivot that includes a 40% workforce reduction and an intensified focus on its core ovarian cancer drug trial. Community sentiment is deeply polarized, with active discussions debating whether the stock is a deep-value buyout target trading below its cash-on-hand valuation or a speculative gamble facing long-term dilution risks.

Coursera, Inc. is an online learning platform, which engages in the provision of online courses and degrees from universities and companies. The firm offers arts, chemistry, engineering, food, and nutrition, health, humanities, law, medicine, and music. It operates through the following segments: Consumer and Enterprise. The Consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers. The Enterprise segment consists of serving businesses, governmental organizations, and academic institutions by providing an intuitive online platform with access to job-relevant educational content enabling them to train, upskill, and reskill their employees, citizens, and students, faculty, and staff, respectively. The company was founded by Daphne Koller and Andrew Y. Ng in 2011 and is headquartered in Mountain View, CA.

Coursera Inc

Coursera is trending as market participants closely monitor its financial performance, with the community actively debating whether the company can successfully navigate the integration of AI into its education platform to drive long-term growth. Discussions remain divided, with some investors betting on a potential rebound from historical lows, while others express skepticism regarding management's ability to monetize products effectively in a competitive EdTech landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharmaceutical Stocks To Follow Today - April 10th

Eli Lilly and Company, Abbott Laboratories, Pfizer, AbbVie, Novo Nordisk A/S, Organon & Co., and Zentalis Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

Organon & Co. Sees Unusually Large Options Volume (NYSE:OGN)

Organon & Co. (NYSE:OGN - Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders bought 20,849 call options on the stock. This is an increase of 537...

Organon, CoreWeave, WhiteFiber And Other Big Stocks Moving Higher On Friday

Dow Jones fell 100 points as Sun Pharma offered 12 billion to buy Organon, Organon shares jumped 26.4%, other stocks also rose.read more...

Organon & Co. (NYSE:OGN) Shares Gap Up - Should You Buy?

Organon & Co. (NYSE:OGN) Shares Gap Up - Still a Buy...

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know  

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In this photo illustration, the Organon logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OGN Stock Surges 20% Pre-Market, On Track To Break 200-DMA – Why This Buyout Report Has Caught Investor Attention

A report stated that Indian pharmaceutical giant Sun Pharma is expected to submit a $12 billion binding offer for the company.

Equity

Organon & Co. (NYSE:OGN) Trading Up 13.1% - Still a Buy?

Organon & Co. (NYSE:OGN) Stock Price Up 13.1% - Still a Buy...

Organon (OGN) Stock Sinks As Market Gains: Here's Why

In the most recent trading session, Organon (OGN) closed at $6.05, indicating a -4.87% shift from the previous trading day.

Philip James Wealth Mangement LLC Lowers Stock Position in Organon & Co. $OGN

Philip James Wealth Mangement LLC cut its stake in shares of Organon & Co. (NYSE:OGN - Free Report) by 48.4% in the fourth quarter, according to the company in its most recent disclosure with the...

Organon & Co. (NYSE:OGN) Short Interest Up 18.7% in March

Organon & Co. (NYSE:OGN - Get Free Report) saw a large increase in short interest in March. As of March 13th, there was short interest totaling 19,323,061 shares, an increase of 18.7% from the...

Warranted - fundamentals justify the decline

Overdone - the market is overreacting

Too early to tell

Is the selloff in software stocks warranted or overdone?

Stocktwits

Stocktwits Polls

Investors are heavily debating the legitimacy and valuation of a potential $12 billion acquisition bid rumored to be from Sun Pharma.

Traders are intensely calculating if a potential takeover accounts for over $8 billion in liabilities or if the valuation is inflated.

Heavy trading volume and massive intraday swings have turned this into a high-stakes binary bet for speculative traders.

Options flow and social buzz are driving short-term trading interest despite company denials and fundamental skepticism.

OGN
Organon & Co.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OGN News

OGNOrganon & Co.